Thus, the response to first-lineplatinum-based chemotherapy in advanced NSCLC with PD-L1 expression of ≤49% could affect the efficacy of second-line ICI monotherapy; however, this has never been investigated. Here, CD274 is linked to non-small cell lung carcinoma.